Bharat Parenterals Intrinsic Value
BPLPHARMA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹968.57 | ₹871.71 - ₹1065.43 | -9.1% | Book Value/Share: ₹484.29, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹777.14 | ₹699.43 - ₹854.85 | -27.1% | Revenue/Share: ₹388.57, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹426.44 | ₹383.80 - ₹469.08 | -60.0% | EBITDA: ₹16.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹426.44 | ₹341.15 - ₹511.73 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| Dividend Yield Method | dividend | ₹319.83 | ₹287.85 - ₹351.81 | -70.0% | DPS: ₹1.00, Target Yield: 2.5% |
Want to compare with current market value? Check BPLPHARMA share price latest .
Valuation Comparison Chart
BPLPHARMA Intrinsic Value Analysis
What is the intrinsic value of BPLPHARMA?
Based on our comprehensive analysis using 5 different valuation methods, the estimated intrinsic value of Bharat Parenterals (BPLPHARMA) is ₹426.44 (median value). With the current market price of ₹1066.10, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹319.83 to ₹968.57, indicating ₹319.83 - ₹968.57.
Is BPLPHARMA undervalued or overvalued?
Based on our multi-method analysis, Bharat Parenterals (BPLPHARMA) appears to be trading above calculated value by approximately 60.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.96 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.91 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | -10.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 1.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.42x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Bharat Parenterals
Additional stock information and data for BPLPHARMA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-27 Cr | ₹-96 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-5 Cr | ₹-58 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹22 Cr | ₹-17 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹-1 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹25 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |